Abstract
In 2020 the PANTS (Personalising Anti-TNF Therapy in Crohn’s Disease) study reported an association between HLADQA1∗05 and the development of antidrug antibodies (ADAs) to infliximab and adalimumab in patients with Crohn’s disease, with 40% of this population carrying this variant.1 The most striking effect of HLADQA1∗05 carriage was on participants treated with infliximab monotherapy: 92% developed ADAs by 1 year, causing the authors to recommend the use of combination therapy in HLADQA1∗05 carriers.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
